Nachrichten zur Biogen Inc. Aktie

ROUNDUP: EU-Behörde lehnt Empfehlung von Alzheimer-Medikament ab

AMSTERDAM (dpa-AFX) - Es wäre die erste zugelassene ursächliche Alzheimer-Therapie in der EU gewesen: Überraschend hat…

European drug regulator rejects Alzheimers treatment Leqembi from Biogen, Eisai

The committee said Leqembis effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen Inc. (BIIB)

LOS ANGELES, July 17, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the…

Friedreichs Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics

The dynamics of Friedreichs ataxia market are anticipated to change as companies across the globe are thoroughly working toward the…

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - BIIB

SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit – BIIB

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

BIIB Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Biogen Inc. (BIIB) Investors of July 22, 2024 Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa., July 14, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

SAN DIEGO, July 13, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

Biogens Diverse Drug Portfolio Faces Competitive Challenges In 2024

…

ANLEIHEN-Woche KW28 - 2024: Noratis, Verve, LEEF, Mutares, Katjes Greenfood, ESPG, MS Industrie, HPI, The Platform Group, Neon Equity, BIOGENA, hep, …

Kalenderwoche 28 am KMU-Anleihemarkt - die Noratis AG strebt eine dreijährige Laufzeit-Verlängerung der Anleihe 2020/25 (ISIN: DE000A3H2TV6) bis zum 31.…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Aktie von Biogen unter Druck: Kurs fällt um 3,83 Prozent (209,1244 €)

Die Aktie von Biogen zählt heute zu den großen Verlierern am Aktienmarkt. Der Kurs des Wertpapiers sackt kräftig ab. Zu…

Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm

NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP notifies investors of…

Biogen: RBC says very likely that Leqembi will be approved in Europe By Investing.com

Biogen: RBC says very likely that Leqembi will be approved in Europe…

Biogen Stock: Cheapish, But With Few Growth Prospects

…

Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights – BIIB

NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biogen Inc. ("Biogen"…

Immunic appoints ex Novartis and Biogen exec as new COO to lead vidofludimus calcium launch

Immunic Inc (NASDAQ:IMUX) told investors it has appointed a former Novartis and Biogen executive as its new chief operating officer to lead internal…

Kessler Topaz Meltzer & Check, LLP Encourages Biogen Inc. Investors with Substantial Loss to Contact the Firm in Regards to Securities Class Action Lawsuit Filed against Biogen Inc.

RADNOR, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Contact The Gross Law Firm by July 22, 2024 Deadline to Join Class Action Against Biogen Inc.(BIIB)

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against Biogen Inc. (BIIB)

RADNOR, Pa., June 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

Biogen Aktie: Erfolg und Kontroversen in China

Eisai und Biogen haben die Markteinführung ihr neuestes Alzheimer-Medikament Leqembi in China bekannt gegeben. Dieses Medikament zielt darauf ab, die…

Eisai and Biogen launch Alzheimers drug Leqembi in China By Reuters

Eisai and Biogen launch Alzheimers drug Leqembi in China…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law…

Biogens nachhaltiger Standort in Solothurn: Auszeichnungen für europäische Produktionsstätte / Schweizer Anlage international mit den Nachhaltigkeitszertifikaten ISO und My Green Lab ausgezeichnet

Biogen GmbH: München (ots) - Nachhaltigkeitsziele, Produktivität und Rentabilität bei Biogen erfolgreich vereint: Alle Labore des Schweizer Standorts Solothurn wurden…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Securities Fraud Class Action Lawsuit Was Filed Against Biogen Inc. (BIIB) – Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., June 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…

Alzheimers Drug Stocks: Investing in Eli Lilly, Biogen, Roche

The race to develop effective Alzheimers treatments presents significant opportunities and inherent risks for healthcare investors.…

BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline

Investors that suffered losses in their Biogen Inc. investment are encouraged to contact BFA Law firm before the July 22,…

Biogen Aktie: Neue Alzheimer-Medikamente Wettstreit

Alzheimer-Markt sieht potenziellen Wandel Nachdem die amerikanische Gesundheitsbehörde FDA im letzten Jahr Leqembi zur Therapie der frühen Alzheimersymptome zugelassen hatte,…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

The Zacks Analyst Blog Highlights Biogen, Eli Lillys, Prothena and AC Immune (Revised)

Biogen, Eli Lillys, Prothena and AC Immune are included in this Analyst Blog.…

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines – BIIB

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…

Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

…

FDA advisors recommend Eli Lillys Alzheimers drug donanemab, paving way for approval

If approved, Eli Lillys donanemab would become the second Alzheimers drug of its kind currently on the U.S. market after…

BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.

Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.…

Biogen, Eisai get January 2025 FDA action date for monthly Leqembi

…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm

NEW YORK, June 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Biogen (BIIB) & Eisais Leqembi sBLA Gets FDA Acceptance

FDA accepts Biogens (BIIB) partner Eisais sBLA for a maintenance intravenous dosing version of Alzheimers drug Leqembi. The final FDA…

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

dpa-AFX ProFeed